Search research articles
Contact Us
Filters
Showing results (581-590 of 701) with videos related to
Page
of 71
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
February 6, 2010
Activation state and intracellular trafficking contribute to the repertoire of endogenous glycosphingolipids presented by CD1d [corrected]
Karen Muindi, Manuela Cernadas, Gerald F M Watts, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 9, 2014
Activation of iNKT cells by a distinct constituent of the endogenous glucosylceramide fraction
Patrick J Brennan, Raju V V Tatituri, Christian Heiss, et al.
Cureus
|
June 28, 2021
Emergent Radiotherapy for Leukemia-Induced Cranial Neuropathies Refractory to Intrathecal Therapy
Nirav Patel, Benjamin J RIch, Shareen Patel, et al.
Leukemia & Lymphoma
|
March 28, 2024
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m<i>IDH1</i>) acute myeloid leukemia (AML)
Jorge Cortes, Brian A Jonas, Gary Schiller, et al.
The American Journal of Tropical Medicine and Hygiene
|
September 3, 2010
Guaroa virus infection among humans in Bolivia and Peru
Patricia V Aguilar, Amy C Morrison, Claudio Rocha, et al.
AIDS (London, England)
|
September 14, 2000
Emerging genetic diversity of HIV-1 in South America
K L Russell, C Carcamo, D M Watts, et al.
The American Journal of Tropical Medicine and Hygiene
|
June 26, 2001
Hepatitis C in Peru: risk factors for infection, potential iatrogenic transmission, and genotype distribution
J L Sanchez, M H Sjogren, J D Callahan, et al.
Leukemia Research
|
August 30, 2016
Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia
Justin M Watts, Bogdan Dumitriu, Patrick Hilden, et al.
Blood Advances
|
July 16, 2025
Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome
Jorge E Cortes, Jay Yang, Gail J Roboz, et al.
British Journal of Haematology
|
December 19, 2024
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm
Stéphane De Botton, Christian Récher, Jorge Cortes, et al.
Page
of 71
Search research articles
Search
Showing results (581-590 of 701) with videos related to
Sort By:
Page
of 71
Proceedings of the National Academy of Sciences of the United States of America
|
February 6, 2010
Activation state and intracellular trafficking contribute to the repertoire of endogenous glycosphingolipids presented by CD1d [corrected]
Karen Muindi, Manuela Cernadas, Gerald F M Watts, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 9, 2014
Activation of iNKT cells by a distinct constituent of the endogenous glucosylceramide fraction
Patrick J Brennan, Raju V V Tatituri, Christian Heiss, et al.
Cureus
|
June 28, 2021
Emergent Radiotherapy for Leukemia-Induced Cranial Neuropathies Refractory to Intrathecal Therapy
Nirav Patel, Benjamin J RIch, Shareen Patel, et al.
Leukemia & Lymphoma
|
March 28, 2024
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m<i>IDH1</i>) acute myeloid leukemia (AML)
Jorge Cortes, Brian A Jonas, Gary Schiller, et al.
The American Journal of Tropical Medicine and Hygiene
|
September 3, 2010
Guaroa virus infection among humans in Bolivia and Peru
Patricia V Aguilar, Amy C Morrison, Claudio Rocha, et al.
AIDS (London, England)
|
September 14, 2000
Emerging genetic diversity of HIV-1 in South America
K L Russell, C Carcamo, D M Watts, et al.
The American Journal of Tropical Medicine and Hygiene
|
June 26, 2001
Hepatitis C in Peru: risk factors for infection, potential iatrogenic transmission, and genotype distribution
J L Sanchez, M H Sjogren, J D Callahan, et al.
Leukemia Research
|
August 30, 2016
Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia
Justin M Watts, Bogdan Dumitriu, Patrick Hilden, et al.
Blood Advances
|
July 16, 2025
Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome
Jorge E Cortes, Jay Yang, Gail J Roboz, et al.
British Journal of Haematology
|
December 19, 2024
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm
Stéphane De Botton, Christian Récher, Jorge Cortes, et al.
Page
of 71